Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Cautious Hold Recommendation for Johnson & Johnson Amid ITCI Acquisition Concerns and Market Challenges
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...
Johnson & Johnson Earnings: Maintaining Fair Value Estimate Despite Heavy Stelara Hit in 2025
J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson’s latest earnings bested Wall Street estimates, as the company braces for one of its top-selling medicines ...
Vulnerable people forced to shield longer ‘because Covid drug was too expensive’
UK’s former vaccine tsar says immunocompromised people were ‘de-prioritised’ in a ‘two-tier’ therapeutic rollout strategy ...
Exclusive: Kennedy played key role in Gardasil vaccine case against Merck
Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...
As bird flu concerns grow, scientists race to develop new vaccines
As fears grow of a possible bird flu pandemic in humans, the federal government is pouring more money into the development of new vaccines, including an mRNA shot.